UNSPSC 51263407: Yohimbine hydrochloride

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C21H26N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NB2E1YP49F, chemically known as 20.alpha.-yohimban-16.beta.-carboxylic acid, 17.alpha.-hydroxy-, methyl ester, monohydrochloride but more generally known as yohimbine hydrochloride, which bears US NIH Compound Identifier 2866. European Medicines Agency schedules Yohimbine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15745MIG.

UNSPSC 51263407 Yohimbine hydrochloride is a Commodity code that describes a specific pharmaceutical product, but the recent state and local opportunities tagged under it show little alignment with yohimbine itself — instead reflecting broader pharmaceutical procurement activity including naloxone, drug deactivation systems, and direct-to-manufacturer prescription program capabilities. State and local issuing bodies purchasing under this code span county health departments and state health agencies. Seminole County, Florida procures naloxone and drug deactivation systems through competitive bidding to support community health initiatives, while the Texas Health and Human Services Commission uses RFI mechanisms to explore direct-to-manufacturer prescription contracting models that could reshape pharmacy benefit delivery across multiple jurisdictions.

The geographic spread of recent activity centers on Florida and Texas, with the Seminole County procurement focused on quarterly deliveries to a single health facility in Sanford, Florida, and the Texas HHS Commission RFI operating at the state level to inform future statewide pharmacy contracting strategy. Seminole County's IFB 60459723LAS sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline, requiring vendors to include shipping costs and comply with E-Verify and drug-free workplace certification; the contract included a two-year initial term with one-year renewal option and potential FEMA funding with associated federal compliance obligations. The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, with an April 3, 2026 response deadline, represents early-stage market intelligence gathering on direct-to-manufacturer prescription capabilities for self-insured employer and state agency health plans, with no award value, formal evaluation criteria, or binding timeline specified at the RFI stage. The mismatch between the code's nominal scope (yohimbine) and the actual procurements suggests either category tagging imprecision or that this code sees limited direct procurement activity in state and local contracting.